For much of the past two years, technology stocks have dominated the market. Companies benefiting from Artificial Intelligence (AI) have delivered tremendous returns, and many investors have naturally become heavily concentrated in the sector.

But markets rarely move in a straight line.

Over the past few months, we've started to see something interesting. While many technology stocks have pulled back from their recent highs, several other sectors have quietly begun attracting fresh buying interest. In particular, the Industrial and Healthcare sectors have continued making higher highs and higher lows, showing signs of relative strength compared to the broader market.

Sector rotation is a normal part of every market cycle. As investors take profits from one area, capital often flows into sectors with improving fundamentals, stronger earnings visibility or better valuations.

Rather than chasing yesterday's winners, it can sometimes pay to look at where institutional money is flowing next.

Today, we'll take a closer look at two market leaders that are benefiting from this shift: Caterpillar (CAT) from the Industrial sector and Eli Lilly (LLY) from the Healthcare sector.

Caterpillar is one of the world's largest manufacturers of heavy machinery and equipment. Its products are used across construction, mining, energy, transportation and infrastructure projects around the globe.

Beyond its iconic yellow construction equipment, Caterpillar has also become an increasingly important player in power generation, supplying large engines and turbines that support industries ranging from oil & gas to rapidly expanding AI data centres.

As governments continue investing in infrastructure while AI drives demand for electricity and energy infrastructure, Caterpillar finds itself serving several long-term growth themes at the same time.

One of the biggest growth drivers today is Power & Energy. Management highlighted that demand for large engines and power generation equipment continues to accelerate, particularly from AI data centres that require reliable electricity. To meet this demand, Caterpillar is expanding production capacity through the end of the decade while securing multi-year framework agreements with customers that provide greater earnings visibility.

The company is also benefiting from improving construction activity. Recent industry reports suggest construction-related demand is recovering, with project starts increasing and infrastructure spending supporting equipment orders. Analysts expect Caterpillar to continue seeing healthy backlog growth and pricing strength as the recovery progresses.

Another encouraging sign is management's continued confidence in returning capital to shareholders. Caterpillar recently announced its 33rd consecutive annual dividend increase, raising its quarterly dividend by almost 8%, reflecting the company's strong cash generation and disciplined capital allocation.

Lastly, Caterpillar continues investing in technology. The recent acquisition of Skycatch strengthens its AI-powered mining capabilities, allowing customers to improve productivity, planning and safety using real-time data and automation.

Eli Lilly is one of the world's largest pharmaceutical companies, developing medicines across diabetes, obesity, cancer, neuroscience and immunology.

While many investors know Lilly because of its blockbuster weight-loss drugs such as Zepbound, the company has built one of the strongest drug pipelines in the healthcare industry, giving it multiple avenues for long-term growth beyond just obesity treatments.

Its global research capabilities and broad product portfolio have helped make it one of the largest healthcare companies in the world.

The biggest growth story remains its leadership in the rapidly expanding GLP-1 weight-loss market. A recent Medicare programme now allows eligible seniors to access GLP-1 weight-loss drugs at significantly lower out-of-pocket costs. Analysts expect this initiative to accelerate prescription growth and potentially add more than US$1 billion in annual revenue for both Lilly and Novo Nordisk as adoption increases.

Lilly also continues expanding globally. The company recently partnered with Innovent Biologics to commercialise its cancer treatment Verzenios in mainland China, strengthening its presence in one of the world's largest healthcare markets.

Beyond current products, Lilly continues investing heavily in future growth. The company was recently selected for the U.S. FDA's PreCheck Pilot Program, designed to accelerate domestic drug manufacturing and improve regulatory efficiency, supporting its long-term pipeline development.

Healthcare has also become one of the stronger-performing sectors in recent months. Several leading pharmaceutical companies, including Eli Lilly, have reached fresh all-time highs as investors rotate toward more defensive sectors with resilient earnings growth. At the same time, industry-wide merger and acquisition activity remains robust, reflecting continued confidence in the sector's long-term outlook.

One of the biggest mistakes investors make is assuming that the market only moves in one direction.

Technology has undoubtedly been one of the strongest sectors over the past few years, but market leadership often rotates. As one sector takes a breather, another may begin attracting fresh institutional capital.

That doesn't necessarily mean investors should sell all their technology holdings. Instead, it serves as a reminder that diversification remains important. By keeping an eye on sectors showing improving relative strength, investors may uncover opportunities that are not yet receiving as much attention.

Caterpillar and Eli Lilly represent two very different businesses, but both are leaders within sectors that have recently shown resilience. Caterpillar is benefiting from infrastructure spending, power generation and AI-related energy demand, while Eli Lilly continues riding powerful long-term healthcare trends through innovation and its expanding pharmaceutical pipeline.

Markets will always rotate.

The key is not trying to predict every move perfectly, but staying open-minded enough to follow where the strength is developing. Sometimes, the next opportunity isn't found in the market's most talked-about sector, but in the one quietly building momentum behind the scenes.

Hope you have found the above stocks useful 😃

If you have yet to be a part of Joey’s VIP clients in Phillip Securities receiving his Exclusive WhatsApp Broadcast daily, you can check it out here!

Joey and team post Top SG Stock Ideas, Market Updates, Research Reports and training videos on a daily basis at NO additional cost.

Look forward to see you on the inside!

- Joey, Bervyn & Zee

Sources:
1. Caterpillar Inc. (CAT) Discusses Capacity Expansion and Engine Solutions for Data Centers and Gas Compression Transcript Available at: https://seekingalpha.com/article/4906150-caterpillar-inc-cat-discusses-capacity-expansion-and-engine-solutions-for-data-centers-and
2.Caterpillar Inc. Increases Dividend. Available at: https://investors.caterpillar.com/news/news-details/2026/Caterpillar-Inc--Increases-Dividend/default.aspx
3. Caterpillar expands mining technology capabilities with Skycatch acquisition. Available at: https://investors.caterpillar.com/news/news-details/2026/Caterpillar-expands-mining-technology-capabilities-with-Skycatch-acquisition/default.aspx
4. Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China. Available at: https://www.prnewswire.com/news-releases/innovent-biologics-and-lilly-enter-into-commercialization-agreement-for-verzenios-abemaciclib-in-mainland-china-302814010.html
5. Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities. Available at: https://www.cnbc.com/2026/06/29/eli-lilly-regeneron-in-fda-precheck-manufacturing-program.html


Note that by subscribing to receive any of Joey's training by email, you agree to allow us to send you the training by email. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of the units in any fund and the income from them may fall as well as rise. If the investment is denominated in a foreign currency, factors including but not limited to changes in exchange rates may have an adverse effect on the value, price or income of an investment. Past performance figures as well as any projection or forecast used in these web pages, are not necessarily indicative of future or likely performance of any investment products. By Accessing this Website and ANY of its pages, you are agreeing to the terms set out ON ALL the following pages as seen below. Copyright © | Joey Choy | All Rights Reserved | Disclaimer | Privacy & Security Policy | Terms and Condition